vs
LUXFER HOLDINGS PLC（LXFR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是LUXFER HOLDINGS PLC的1.4倍（$127.1M vs $90.7M），再鼎医药同比增速更快（17.1% vs -12.3%），LUXFER HOLDINGS PLC自由现金流更多（$12.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.7%）
Luxfer Holdings PLC是一家全球性工业制造商，专注于高性能工程材料及零部件生产，核心产品包括轻量化铝制及复合材料储气系统、先进合金与特种材料，服务航空航天、医疗保健、汽车、工业制造、替代能源等全球多个核心领域。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LXFR vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$90.7M
营收增速更快
ZLAB
高出29.4%
-12.3%
自由现金流更多
LXFR
多$39.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.7M | $127.1M |
| 净利润 | $-3.1M | — |
| 毛利率 | 24.4% | 51.0% |
| 营业利润率 | 3.6% | -54.6% |
| 净利率 | -3.4% | — |
| 营收同比 | -12.3% | 17.1% |
| 净利润同比 | -188.6% | — |
| 每股收益（稀释后） | $-0.12 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXFRZLAB
| Q4 25 | $90.7M | $127.1M | ||
| Q3 25 | $92.9M | $115.4M | ||
| Q2 25 | $104.0M | $109.1M | ||
| Q1 25 | $97.0M | $105.7M | ||
| Q4 24 | $103.4M | $108.5M | ||
| Q3 24 | $99.4M | $101.8M | ||
| Q2 24 | $99.7M | $100.1M | ||
| Q1 24 | $89.4M | $87.1M |
净利润LXFRZLAB
| Q4 25 | $-3.1M | — | ||
| Q3 25 | $2.7M | $-36.0M | ||
| Q2 25 | $2.6M | $-40.7M | ||
| Q1 25 | $5.5M | $-48.4M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $12.7M | $-41.7M | ||
| Q2 24 | $-500.0K | $-80.3M | ||
| Q1 24 | $2.7M | $-53.5M |
毛利率LXFRZLAB
| Q4 25 | 24.4% | 51.0% | ||
| Q3 25 | 23.4% | 59.5% | ||
| Q2 25 | 23.1% | 60.6% | ||
| Q1 25 | 22.1% | 63.6% | ||
| Q4 24 | 22.1% | 61.5% | ||
| Q3 24 | 22.5% | 64.1% | ||
| Q2 24 | 22.1% | 64.9% | ||
| Q1 24 | 20.6% | 61.4% |
营业利润率LXFRZLAB
| Q4 25 | 3.6% | -54.6% | ||
| Q3 25 | 5.8% | -42.3% | ||
| Q2 25 | 7.4% | -50.3% | ||
| Q1 25 | 7.8% | -53.3% | ||
| Q4 24 | 3.9% | -62.6% | ||
| Q3 24 | 17.5% | -66.6% | ||
| Q2 24 | 3.8% | -76.0% | ||
| Q1 24 | 5.5% | -80.7% |
净利率LXFRZLAB
| Q4 25 | -3.4% | — | ||
| Q3 25 | 2.9% | -31.2% | ||
| Q2 25 | 2.5% | -37.3% | ||
| Q1 25 | 5.7% | -45.8% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 12.8% | -40.9% | ||
| Q2 24 | -0.5% | -80.2% | ||
| Q1 24 | 3.0% | -61.4% |
每股收益（稀释后）LXFRZLAB
| Q4 25 | $-0.12 | $-0.05 | ||
| Q3 25 | $0.10 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $0.20 | $-0.04 | ||
| Q4 24 | $0.13 | $-0.09 | ||
| Q3 24 | $0.47 | $-0.04 | ||
| Q2 24 | $-0.02 | $-0.08 | ||
| Q1 24 | $0.10 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $689.6M |
| 总债务越低越好 | $39.4M | — |
| 股东权益账面价值 | $226.4M | $715.5M |
| 总资产 | $369.7M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资LXFRZLAB
| Q4 25 | $8.3M | $689.6M | ||
| Q3 25 | $6.0M | $717.2M | ||
| Q2 25 | $4.4M | $732.2M | ||
| Q1 25 | $4.1M | $757.3M | ||
| Q4 24 | $4.1M | $779.7M | ||
| Q3 24 | $3.5M | $616.1M | ||
| Q2 24 | $4.3M | $630.0M | ||
| Q1 24 | $6.8M | $650.8M |
总债务LXFRZLAB
| Q4 25 | $39.4M | — | ||
| Q3 25 | $43.3M | — | ||
| Q2 25 | $52.6M | — | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $45.1M | — | ||
| Q3 24 | $69.5M | — | ||
| Q2 24 | $74.2M | — | ||
| Q1 24 | $78.4M | — |
股东权益LXFRZLAB
| Q4 25 | $226.4M | $715.5M | ||
| Q3 25 | $231.6M | $759.9M | ||
| Q2 25 | $237.7M | $791.7M | ||
| Q1 25 | $226.7M | $810.8M | ||
| Q4 24 | $219.5M | $840.9M | ||
| Q3 24 | $225.1M | $667.7M | ||
| Q2 24 | $206.3M | $704.2M | ||
| Q1 24 | $210.3M | $762.2M |
总资产LXFRZLAB
| Q4 25 | $369.7M | $1.2B | ||
| Q3 25 | $377.4M | $1.2B | ||
| Q2 25 | $399.2M | $1.2B | ||
| Q1 25 | $385.2M | $1.2B | ||
| Q4 24 | $382.4M | $1.2B | ||
| Q3 24 | $404.8M | $985.3M | ||
| Q2 24 | $379.8M | $987.4M | ||
| Q1 24 | $386.0M | $988.4M |
负债/权益比LXFRZLAB
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $12.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 13.7% | -21.0% |
| 资本支出强度资本支出/营收 | 3.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $26.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LXFRZLAB
| Q4 25 | $15.6M | $-26.0M | ||
| Q3 25 | $11.8M | $-32.0M | ||
| Q2 25 | $1.2M | $-31.0M | ||
| Q1 25 | $5.4M | $-61.7M | ||
| Q4 24 | $25.5M | $-55.8M | ||
| Q3 24 | $13.0M | $-26.8M | ||
| Q2 24 | $8.9M | $-42.2M | ||
| Q1 24 | $3.7M | $-90.1M |
自由现金流LXFRZLAB
| Q4 25 | $12.4M | $-26.7M | ||
| Q3 25 | $10.3M | $-35.0M | ||
| Q2 25 | $-700.0K | $-33.9M | ||
| Q1 25 | $4.2M | $-63.2M | ||
| Q4 24 | $22.5M | $-58.4M | ||
| Q3 24 | $9.8M | $-28.2M | ||
| Q2 24 | $6.2M | $-42.9M | ||
| Q1 24 | $2.3M | $-91.1M |
自由现金流率LXFRZLAB
| Q4 25 | 13.7% | -21.0% | ||
| Q3 25 | 11.1% | -30.4% | ||
| Q2 25 | -0.7% | -31.1% | ||
| Q1 25 | 4.3% | -59.9% | ||
| Q4 24 | 21.8% | -53.8% | ||
| Q3 24 | 9.9% | -27.7% | ||
| Q2 24 | 6.2% | -42.9% | ||
| Q1 24 | 2.6% | -104.5% |
资本支出强度LXFRZLAB
| Q4 25 | 3.5% | 0.5% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 1.2% | 1.5% | ||
| Q4 24 | 2.9% | 2.4% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 2.7% | 0.7% | ||
| Q1 24 | 1.6% | 1.1% |
现金转化率LXFRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 4.37× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 7.29× | — | ||
| Q3 24 | 1.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXFR
| Gas Cylinders Segment | $43.8M | 48% |
| Defense First Response And Healthcare | $18.6M | 21% |
| Rest Of Europe | $9.0M | 10% |
| DE | $7.0M | 8% |
| Asia Pacific | $5.8M | 6% |
| CA | $4.0M | 4% |
| Other | $2.5M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
